Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use. 1985

G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White

UI MeSH Term Description Entries
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250
D014191 Tranylcypromine A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311) Jatrosom,Parnate,Transamine,Tranylcypromine Sulfate,trans-2-Phenylcyclopropylamine,Sulfate, Tranylcypromine,trans 2 Phenylcyclopropylamine

Related Publications

G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
January 1980, Journal of neural transmission. Supplementum,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
January 1982, European journal of clinical pharmacology,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
January 1972, Advances in biochemical psychopharmacology,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
January 1991, DICP : the annals of pharmacotherapy,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
January 1989, Journal of neural transmission. Parkinson's disease and dementia section,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
December 1981, The Journal of pharmacy and pharmacology,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
October 1980, Biochemical pharmacology,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
October 2023, Therapeutic drug monitoring,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
July 1997, Journal of clinical pharmacology,
G M Simpson, and E Frederickson, and R Palmer, and E Pi, and R B Sloane, and K White
February 1986, Psychiatry research,
Copied contents to your clipboard!